New pill shows promise in early trial for Hard-to-Treat cancers

NCT ID NCT07029399

First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 23 times

Summary

This early-stage study tests an experimental oral drug, NKT5097, in adults with advanced solid tumors that have not responded to other treatments. The main goals are to find a safe dose and understand side effects. About 205 participants with breast, ovarian, endometrial, or other cancers will take the drug and be monitored closely.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cleveland Clinic

    RECRUITING

    Cleveland, Ohio, 44195, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact

    Contact Phone: •••-•••-••••

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • NEXT Virginia

    RECRUITING

    Fairfax, Virginia, 22031, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • SCRI Florida Cancer Specialists - Sarasota

    RECRUITING

    Sarasota, Florida, 34232, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Sarah Cannon Research Institute at HealthONE

    RECRUITING

    Denver, Colorado, 80218, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • South Texas Accelerated Research Therapeutics (START) Midwest

    RECRUITING

    Grand Rapids, Michigan, 49546, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • South Texas Accelerated Research Therapeutics (START) Mountain Region

    RECRUITING

    West Valley City, Utah, 84119, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • South Texas Accelerated Research Therapeutics (START) San Antonio

    RECRUITING

    San Antonio, Texas, 78229, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • UC San Diego Moores Cancer Center

    RECRUITING

    La Jolla, California, 92037, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • UPMC Hillman Cancer Center

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Texas Southwestern Medical Center

    RECRUITING

    Dallas, Texas, 75390, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Washington University

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Yale Cancer Center

    RECRUITING

    New Haven, Connecticut, 06520, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.